Our
Research
One of the greatest challenges that we face in discovering new disease therapies is that most proteins are considered “undruggable.” Our research group is reimagining druggability by using chemoproteomic approaches to tackle the undruggable proteome.
Featured Publications
Targeted transcriptional repression by induced proximity
Stieger CE, Chen X, Dovala D, Wu F, Pizzato N, McKenna J, Johannessen C, Fodor BD, Schirle M, Nomura DK.
BioRxiv, 2025, doi: https://doi.org/10.1101/2025.10.22.680877.
Sulfinyl aziridines as stereoselective covalent destabilizing degraders of the oncogenic transcription factor MYC
Rosen HT*, Li K*, Stieger CE, Li E, Currier B, Brittain SM, Garcia FJ, Beard DC, Jones MD, Haenni-Holzinger S, Dovala D, McKenna JM, Schirle M, Maimone TJ#, Nomura DK#.
Angewandte Chemie International Edition, 2025, doi: 10.1002/anie.202508518. PMID 400999784 (*co-first authors; # co-corresponding authors)
Rational Chemical Design of Molecular Glue Degraders
Toriki ES*, Papatzimas JW*, Nishikawa K, Dovala D, Frank AO, Hesse MJ, Dankova D, Song J-G, Bruce-Smythe M, Struble H, Garcia FJ, Brittain SM, Kile AC, McGregor LM, McKenna JM, Tallarico JA, Schirle M, Nomura DK
ACS Central Science, 2023, 9, 915-926. (* co-first authorship)
(Novartis-Berkeley Translational Chemical Biology Institute paper)
Our new Biorxiv preprint on targeted transcriptional repression with TRACERs!
Our new Lab photo!
Congrats to Nafsika Forte for her paper on covalent recruitment of E2’s for targeted protein degradation
Congrats to Ethan Toriki and James Papaztimas on their discovery of rational chemical design strategies for molecular glue degraders
Vicinitas Therapeutics Launches With $65 Million in Series A Financing to Advance Precision Medicines to Stabilize Key Proteins to Treat Disease
